SPECIALTY GUIDELINE MANAGEMENT

OLYSIO (simeprevir)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

Olysio is indicated for the treatment of adults with chronic hepatitis C virus (HCV) infection:

- A. in combination with sofosbuvir in patients with HCV genotype 1 without cirrhosis or with compensated cirrhosis
- B. in combination with peginterferon alfa (PEG-IFN) and ribavirin (RBV) in patients with HCV genotype 1 or 4 without cirrhosis or with compensated cirrhosis

All other indications are considered experimental/investigational and are not medically necessary.

II. EXCLUSIONS

Coverage will not be provided for members with decompensated cirrhosis/moderate or severe hepatic impairment (Child Turcotte Pugh Class B or C).

Note: When the requested drug is being used in a combination therapy regimen, exclusions to the other antiviral drugs also apply.

III. INITIAL CRITERIA FOR APPROVAL

A. Chronic hepatitis C virus infection, in combination with PEG-IFN and RBV

1. Genotype 1 or 4 infection

Authorization of up to 6 weeks total may be granted for initiation of therapy in members who are treatment-naïve or failed prior treatment with PEG-IFN and RBV AND meet one of the following criteria:

- a. Genotype 1a infection without the NS3 Q80K polymorphism
- b. Genotype 1b infection
- c. Genotype 4 infection

B. Chronic hepatitis C virus infection, in combination with Sovaldi

1. Genotype 1a infection

- a. Authorization of up to 12 weeks total may be granted for members without cirrhosis who are treatment-naïve or failed prior treatment with PEG-IFN and RBV.
- Authorization of up to 24 weeks total may be granted for members with compensated cirrhosis without the NS3 Q80K polymorphism who are treatment-naïve or failed prior treatment with PEG-IFN and RBV.

Olysio 2138-A, 2679-A SGM P2019.docx

© 2020 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



Reference number(s) 2138-A, 2679-A

2. Genotype 1b infection

- a. Authorization of up to 12 weeks total may be granted for members without cirrhosis who are treatment-naïve or failed prior treatment with PEG-IFN and RBV.
- b. Authorization of up to 24 weeks total may be granted for members with compensated cirrhosis who are treatment-naïve or failed prior treatment with PEG-IFN and RBV.

C. HCV and HIV Coinfection

Authorization may be granted for members with HCV and HIV coinfection when the criteria for approval of the requested regimen in Section A, B or C above are met.


IV. CONTINUATION OF THERAPY

Chronic hepatitis C virus infection, in combination with PEG-IFN and RBV Genotype 1 or 4 infection at week 4 assessment

Authorization of up to 12 weeks total for Olysio and up to 48 weeks total for PEG-IFN and RBV may be granted for members with HCV-RNA < 25 IU/mL at week 4 of treatment.

V. REFERENCES

1. Olysio [package insert]. Titusville, NJ: Janssen Products, LP; November 2017.



°CVS caremark™